Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  HIV Infection

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 56 articles:
HTML format
Text format



Single Articles


    November 2018
  1. KOCHHAR S, Excler JL, Bok K, Gurwith M, et al
    Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines.
    Vaccine. 2018 Nov 26. pii: S0264-410X(18)31235.
    PubMed     Text format     Abstract available


  2. MCMORROW ML, Tempia S, Walaza S, Treurnicht FK, et al
    Prioritization of risk groups for influenza vaccination in resource limited settings - A case study from South Africa.
    Vaccine. 2018 Nov 21. pii: S0264-410X(18)31573.
    PubMed     Text format     Abstract available


  3. HURLEY LP, Allison MA, Dooling KL, O'Leary ST, et al
    Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV).
    Vaccine. 2018;36:7408-7414.
    PubMed     Text format     Abstract available


  4. NAKIBONEKA R, Mugaba S, Auma BO, Kintu C, et al
    Interferon gamma (IFN-gamma) negative CD4+ and CD8+ T-cells can produce immune mediators in response to viral antigens.
    Vaccine. 2018 Nov 17. pii: S0264-410X(18)31547.
    PubMed     Text format     Abstract available


    October 2018
  5. JI Y, Han X, Tian W, Gao Y, et al
    V4 region of the HIV-1 envelope gene mediates immune escape and may not promote the development of broadly neutralizing antibodies.
    Vaccine. 2018 Oct 30. pii: S0264-410X(18)31471.
    PubMed     Text format     Abstract available


  6. HADDISON EC, Ngono D, Kouamen GT, Kagina BM, et al
    Successful polio supplementary immunisation activities in a security compromised zone - Experiences from the Southwest region of Cameroon.
    Vaccine. 2018 Oct 9. pii: S0264-410X(18)31356.
    PubMed     Text format     Abstract available


  7. MUGO NR, Eckert L, Magaret AS, Cheng A, et al
    Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status.
    Vaccine. 2018 Oct 5. pii: S0264-410X(18)31328.
    PubMed     Text format     Abstract available


    September 2018
  8. PURWAR M, Pokorski JK, Singh P, Bhattacharyya S, et al
    Design, display and immunogenicity of HIV1 gp120 fragment immunogens on virus-like particles.
    Vaccine. 2018 Sep 14. pii: S0264-410X(18)31001.
    PubMed     Text format     Abstract available


  9. DENDLE C, Stuart RL, Mulley WR, Holdsworth SR, et al
    Pneumococcal vaccination in adult solid organ transplant recipients: A review of current evidence.
    Vaccine. 2018 Sep 11. pii: S0264-410X(18)31209.
    PubMed     Text format     Abstract available


  10. ELBAHNASAWY MA, Donius LR, Reinherz EL, Kim M, et al
    Co-delivery of a CD4 T cell helper epitope via covalent liposome attachment with a surface-arrayed B cell target antigen fosters higher affinity antibody responses.
    Vaccine. 2018 Sep 6. pii: S0264-410X(18)31123.
    PubMed     Text format     Abstract available


    August 2018
  11. DAMJANOVIC D, He L, Symes J, Gajewska B, et al
    In vitro assessment of biological activity and stability of the ALVAC-HIV vaccine.
    Vaccine. 2018 Aug 10. pii: S0264-410X(18)31003.
    PubMed     Text format     Abstract available


  12. NADARZYNSKI T, Smith H, Richardson D, Bremner S, et al
    Men who have sex with men who do not access sexual health clinics nor disclose sexual orientation are unlikely to receive the HPV vaccine in the UK.
    Vaccine. 2018;36:5065-5070.
    PubMed     Text format     Abstract available


  13. PATRICIA D'SOUZA M, Allen MA, Baumblatt JAG, Boggiano C, et al
    Innovative approaches to track lymph node germinal center responses to evaluate development of broadly neutralizing antibodies in human HIV vaccine trials.
    Vaccine. 2018 Aug 7. pii: S0264-410X(18)31080.
    PubMed     Text format     Abstract available


  14. SPINA FG, Gouvea A, Succi RCM, Calanca F, et al
    Immune response to a Tdap booster in vertically HIV-infected adolescents.
    Vaccine. 2018 Aug 4. pii: S0264-410X(18)31012.
    PubMed     Text format     Abstract available


  15. ITELL HL, McGuire EP, Muresan P, Cunningham CK, et al
    Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines.
    Vaccine. 2018 Aug 4. pii: S0264-410X(18)31017.
    PubMed     Text format     Abstract available


    July 2018
  16. VIRNIK K, Nesti E, Dail C, Scanlan A, et al
    Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost.
    Vaccine. 2018 Jul 20. pii: S0264-410X(18)30940.
    PubMed     Text format     Abstract available


  17. APAYDIN KZ, Fontenot HB, Borba CPC, Shtasel DL, et al
    Three-dose HPV vaccine completion among sexual and gender minority young adults at a Boston community health center.
    Vaccine. 2018 Jul 5. pii: S0264-410X(18)30898.
    PubMed     Text format     Abstract available


    June 2018
  18. LIU W, Wong YC, Chen SMY, Tang J, et al
    DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses.
    Vaccine. 2018 Jun 28. pii: S0264-410X(18)30888.
    PubMed     Text format     Abstract available


  19. TAN N, Sharma M, Winer R, Galloway D, et al
    Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa.
    Vaccine. 2018 Jun 8. pii: S0264-410X(18)30197.
    PubMed     Text format     Abstract available


  20. CHESSON HW, Meites E, Ekwueme DU, Saraiya M, et al
    Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26years in the United States.
    Vaccine. 2018 Jun 7. pii: S0264-410X(18)30578.
    PubMed     Text format     Abstract available


    May 2018
  21. FLEMING JA, Baltrons R, Rowley E, Quintanilla I, et al
    Implementation of maternal influenza immunization in El Salvador: Experiences and lessons learned from a mixed-methods study.
    Vaccine. 2018 May 30. pii: S0264-410X(18)30762.
    PubMed     Text format     Abstract available


  22. ZHANG W, Sun H, Atiquzzaman M, Sou J, et al
    Influenza vaccination for HIV-positive people: Systematic review and network meta-analysis.
    Vaccine. 2018 May 30. pii: S0264-410X(18)30743.
    PubMed     Text format     Abstract available


  23. DAMILANO GD, Sued O, Ruiz MJ, Ghiglione Y, et al
    Computational comparison of availability in CTL/gag epitopes among patients with acute and chronic HIV-1 infection.
    Vaccine. 2018 May 22. pii: S0264-410X(18)30606.
    PubMed     Text format     Abstract available


    April 2018
  24. LU PJ, O'Halloran AC, Williams WW, Nelson NP, et al
    Hepatitis B vaccination coverage among adults aged >/=18years traveling to a country of high or intermediate endemicity, United States, 2015.
    Vaccine. 2018 Apr 28. pii: S0264-410X(18)30376.
    PubMed     Text format     Abstract available


  25. IBARZ-PAVON AB, French N
    No changes on viral load and CD4+ T-cell counts following immunization with 7-valent pneumococcal conjugate vaccine among HIV-infected adults in Malawi.
    Vaccine. 2018 Apr 7. pii: S0264-410X(18)30478.
    PubMed     Text format     Abstract available


  26. LAPUENTE D, Ruzsics Z, Thirion C, Tenbusch M, et al
    Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses.
    Vaccine. 2018 Apr 5. pii: S0264-410X(18)30262.
    PubMed     Text format     Abstract available


  27. SPICKNALL IH, Looker KJ, Gottlieb SL, Chesson HW, et al
    Review of mathematical models of HSV-2 vaccination: Implications for vaccine development.
    Vaccine. 2018 Apr 3. pii: S0264-410X(18)30254.
    PubMed     Text format     Abstract available


    March 2018
  28. WORLD HEALTH ORGANIZATION
    BCG vaccine: WHO position paper, February 2018 - Recommendations.
    Vaccine. 2018 Mar 30. pii: S0264-410X(18)30345.
    PubMed     Text format     Abstract available


  29. HARRER T, Dinges W, Roman F
    Long-term follow-up of HIV-1-infected adults who received the F4/AS01B HIV-1 vaccine candidate in two randomised controlled trials.
    Vaccine. 2018 Mar 29. pii: S0264-410X(18)30388.
    PubMed     Text format     Abstract available


  30. LU PJ, O'Halloran AC, Williams WW, Nelson NP, et al
    Hepatitis B vaccination coverage among adults aged>/=18years traveling to a country of high or intermediate endemicity, United States, 2015.
    Vaccine. 2018 Mar 28. pii: S0264-410X(18)30375.
    PubMed     Text format     Abstract available


  31. PANDEY RK, Ojha R, Aathmanathan VS, Krishnan M, et al
    Immunoinformatics approaches to design a novel multi-epitope subunit vaccine against HIV infection.
    Vaccine. 2018 Mar 20. pii: S0264-410X(18)30387.
    PubMed     Text format     Abstract available


    February 2018
  32. THIAM-DIOUF A, Metch B, Sharpe C, Mulugeta R, et al
    Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention.
    Vaccine. 2018;36:1235-1242.
    PubMed     Text format     Abstract available


  33. KOURKOUNTI S, Retsas T, Paparizos V, Tsimpidakis A, et al
    Evaluation of a convenient vaccination schedule against hepatitis B in HIV-patients with undetectable HIV viral load.
    Vaccine. 2018 Feb 12. pii: S0264-410X(18)30192.
    PubMed     Text format     Abstract available


  34. NELSON NP, Yankey D, Singleton JA, Elam-Evans LD, et al
    Hepatitis A vaccination coverage among adolescents (13-17years) in the United States, 2008-2016.
    Vaccine. 2018 Feb 12. pii: S0264-410X(18)30163.
    PubMed     Text format     Abstract available


  35. SHRIVASTAVA T, Samal S, Tyagi AK, Goswami S, et al
    Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response.
    Vaccine. 2018 Feb 8. pii: S0264-410X(18)30154.
    PubMed     Text format     Abstract available


    January 2018
  36. DE BOER PT, Kelso JK, Halder N, Nguyen TP, et al
    The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.
    Vaccine. 2018 Jan 17. pii: S0264-410X(17)31836.
    PubMed     Text format     Abstract available


    December 2017
  37. SERWANGA J, Ssemwanga D, Muganga M, Nakiboneka R, et al
    HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies.
    Vaccine. 2017 Dec 20. pii: S0264-410X(17)31718.
    PubMed     Text format     Abstract available


  38. SHIVE CL, Judge CJ, Clagett B, Kalayjian RC, et al
    Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.
    Vaccine. 2017 Dec 15. pii: S0264-410X(17)31761.
    PubMed     Text format     Abstract available


  39. HIBBS BF, Miller E, Shi J, Smith K, et al
    Safety of vaccines that have been kept outside of recommended temperatures: Reports to the Vaccine Adverse Event Reporting System (VAERS), 2008-2012.
    Vaccine. 2017 Dec 13. pii: S0264-410X(17)31726.
    PubMed     Text format     Abstract available


  40. HABER P, Moro PL, Ng C, Lewis PW, et al
    Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.
    Vaccine. 2017 Dec 11. pii: S0264-410X(17)31722.
    PubMed     Text format     Abstract available


  41. HERBECK JT, Peebles K, Edlefsen PT, Rolland M, et al
    HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine.
    Vaccine. 2017 Dec 11. pii: S0264-410X(17)31731.
    PubMed     Text format     Abstract available


  42. GOTTLIEB SL, Giersing BK, Hickling J, Jones R, et al
    Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017.
    Vaccine. 2017 Dec 7. pii: S0264-410X(17)31492.
    PubMed     Text format     Abstract available


    November 2017
  43. WENIGER BG, Anglin IE, Tong T, Pensiero M, et al
    Workshop report: Nucleic acid delivery devices for HIV vaccines: Workshop proceedings, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, May 21, 2015.
    Vaccine. 2017 Nov 21. pii: S0264-410X(17)31479.
    PubMed     Text format     Abstract available


  44. NANNI A, Meredith S, Gati S, Holm K, et al
    Strengthening global vaccine access for adolescents and adults.
    Vaccine. 2017 Nov 6. pii: S0264-410X(17)31419.
    PubMed     Text format     Abstract available


    October 2017
  45. FROTA ACC, Ferreira B, Harrison LH, Pereira GS, et al
    Safety and immune response after two-dose meningococcal C conjugate immunization in HIV-infected children and adolescents in Rio de Janeiro, Brazil.
    Vaccine. 2017 Oct 31. pii: S0264-410X(17)31451.
    PubMed     Text format     Abstract available


  46. SHIRATSUCHI T, Rai U, Kaneko I, Zhang M, et al
    A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII.
    Vaccine. 2017 Oct 28. pii: S0264-410X(17)31474.
    PubMed     Text format     Abstract available


  47. SLEZAK J, Meyer K, Sy LS, Chao C, et al
    An imputation method for calculating and comparing autoimmune disease incidence using partial case review.
    Vaccine. 2017 Oct 24. pii: S0264-410X(17)31418.
    PubMed     Text format     Abstract available


  48. IZURIETA HS, Moro PL, Chen RT
    Hospital-based collaboration for epidemiological investigation of vaccine safety: A potential solution for low and middle-income countries?
    Vaccine. 2017 Oct 12. pii: S0264-410X(17)31365.
    PubMed     Text format    


  49. WU J, Zhao C, Liu Q, Huang W, et al
    Development and application of a bioluminescent imaging mouse model for Chikungunya virus based on pseudovirus system.
    Vaccine. 2017 Oct 11. pii: S0264-410X(17)31371.
    PubMed     Text format     Abstract available


  50. ANA-SOSA-BATIZ F, Johnston APR, Hogarth PM, Wines BD, et al
    Antibody-dependent phagocytosis (ADP) responses following trivalent inactivated influenza vaccination of younger and older adults.
    Vaccine. 2017 Oct 10. pii: S0264-410X(17)31315.
    PubMed     Text format     Abstract available


  51. SUN P, Crum-Cianflone NF, Defang G, Williams M, et al
    Evaluation of T and B memory cell responses elicited by the pandemic H1N1 vaccine in HIV-infected and HIV-uninfected individuals.
    Vaccine. 2017 Oct 4. pii: S0264-410X(17)31307.
    PubMed     Text format     Abstract available


    September 2017
  52. NONZEE NJ, Baldwin SB, Cui Y, Singhal R, et al
    Disparities in parental human papillomavirus (HPV) vaccine awareness and uptake among adolescents.
    Vaccine. 2017 Sep 26. pii: S0264-410X(17)31134.
    PubMed     Text format     Abstract available


  53. CHENG L, Zhang Z, Li G, Li F, et al
    Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system.
    Vaccine. 2017 Sep 25. pii: S0264-410X(17)31300.
    PubMed     Text format     Abstract available


  54. SCHIFFER JT, Gottlieb SL
    Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.
    Vaccine. 2017 Sep 25. pii: S0264-410X(17)31273.
    PubMed     Text format     Abstract available


  55. TAN S, Zhang S, Wu B, Zhao Y, et al
    Hemagglutinin-specific CD4+ T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans.
    Vaccine. 2017 Sep 13. pii: S0264-410X(17)31159.
    PubMed     Text format     Abstract available


  56. SUNDARAMURTHI JC, Ashokkumar M, Swaminathan S, Hanna LE, et al
    HLA based selection of epitopes offers a potential window of opportunity for vaccine design against HIV.
    Vaccine. 2017 Sep 6. pii: S0264-410X(17)31168.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: